Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Castration-Resistant Prostate Cancer Patients 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × irofulven × Clear all
NCT00005031 2013-05-27

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

GOG Foundation

Phase 2 Completed
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡